Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed HER2-positive MBC~* Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery~* Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment~* Stable systemic disease~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* LVEF at least 50%~* Adequate hematologic, renal, and hepatic function~* Life expectancy more than 12 weeks~Exclusion Criteria:~* Progression of systemic disease at Screening~* Leptomeningeal disease~* History of intolerance or hypersensitivity to study drug~* Use of certain investigational therapies within 21 days prior to enrollment~* Current anthracycline use~* Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use~* Active infection~* Pregnant or lactating women~* Significant history or risk of cardiac disease~* Symptomatic intrinsic lung disease or lung involvement~* History of other malignancy within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertuzumab + Trastuzumab (Type: EXPERIMENTAL): Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

Based on this trial design, predict the completion outcome and termination type (if applicable).